Please assess the completion status of the following clinical trial:

Trial Title: Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* End-stage renal disease awaiting transplantation on the UNOS list.~* No known contraindications for therapy with IVIG10%/Rituximab, plasmapheresis (PLEX) or IdeS®.~* Age 18-70 years at the time of screening.~* Calculated PRA (CPRA)\> 50% demonstrated on 3 consecutive samples, Patient highly-HLA sensitized and a candidate for DD transplantation after desensitization at CSMC.~* At transplant, patient must have donor-specific antibody/ crossmatch positive (DSA/CMX+) non-HLA identical donor.~* Pre-transplant vaccination with Streptococcus pneumoniae and Nisseria meningitides~* Subject/Parent/Guardian must be able to understand and provide informed consent.~Exclusion Criteria:~* Positivity for anti-IdeS IgE~* Use of IVIG 4 weeks prior to planned IdeS® administration~* Recipients of Extended Criteria Donors (ECD) or Living Donors (LD)~* Lactating or pregnant females.~* Women of child-bearing age who are not willing or able to practice FDA-approved forms of contraception.~* HIV-positive subjects.~* Subjects who test positive for HBV infection \[positive HBVsAg, HBVcAb, or HBVeAg/DNA\] or HCV infection \[positive Anti-HCV (EIA) and confirmatory HCV RIBA\].~* Subjects with active TB.~* Subjects with selective IgA deficiency, those who have known anti-IgA antibodies, and those with a history of anaphylaxis or severe systemic responses to any part of the clinical trial material.~* Subjects who have received or for whom multiple organ transplants are planned.~* Recent recipients of any licensed or investigational live attenuated vaccine(s) within two months of the screening visit (including but not limited to any of the following:~  1. Adenovirus \[Adenovirus vaccine live oral type 7\]~ 2. Varicella \[Varivax\]~ 3. Hepatitis A \[VAQTA\]~ 4. Rotavirus \[Rotashield\]~ 5. Yellow fever \[Y-F-Vax\]~ 6. Measles and mumps \[Measles and mumps virus vaccine live\]~ 7. Measles, mumps, and rubella vaccine \[M-M-R-II\]~ 8. Sabin oral polio vaccine~ 9. Rabies vaccines \[IMOVAX Rabies I.D., RabAvert\])~* A significantly abnormal general serum screening lab result defined as a WBC \< 3.0 X 103/ml, a Hgb \< 8.0 g/dL, a platelet count \< 100 X 103/ml, , an SGOT \> 3X upper limit .~* Individuals deemed unable to comply with the protocol.~* Subjects with active CMV or EBV infection as defined by CMV-specific serology (IgG or IgM) and confirmed by quantitative PCR with or without a compatible illness.~* Subjects with a known history of previous myocardial infarction within one year of screening.~* Subjects with a history of clinically significant thrombotic episodes, and subjects with active peripheral vascular disease.~* Subjects with Protein C and Protein S deficiency~* Use of investigational agents within 4 weeks of participation.~* Known allergy/sensitivity to IdeS® infusions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- IdeS® (Type: EXPERIMENTAL): Twenty patients will receive 0.24mg/kg (n=20)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete